Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cereblon-Cullin 4 E3 ubiquitin ligase complex (CRL4-CRBN) is a multi-subunit enzyme complex that plays a pivotal role in the ubiquitin-proteasome system by mediating the polyubiquitination of specific substrate proteins [1, 2]. The complex is composed of the substrate receptor Cereblon (CRBN), the adaptor protein DNA damage-binding protein 1 (DDB1), the scaffold protein Cullin 4 (CUL4A or CUL4B), and the RING-finger protein RBX1 [2, 3]. CRL4-CRBN gained significant clinical prominence as the primary molecular target of immunomodulatory imide drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide [3, 4]. These drugs function as molecular glues, binding to the CRBN subunit and altering its surface to recruit "neo-substrates"—proteins not normally targeted by the ligase—such as the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) [4, 5]. The subsequent degradation of these factors is essential for the anti-proliferative and immunomodulatory effects observed in the treatment of multiple myeloma and myelodysplastic syndromes [5, 6]. Additionally, the CRL4-CRBN complex is a cornerstone of targeted protein degradation (TPD) technology, serving as the E3 ligase component for many Proteolysis-Targeting Chimeras (PROTACs) designed to eliminate diverse pathogenic proteins [7]. Beyond its role in cancer therapy, mutations in the CRBN subunit are associated with autosomal recessive intellectual disability, and its interaction with thalidomide is responsible for the drug's well-known teratogenic effects during limb development [1, 3, 9].
The complex acts as a scaffold for the E3 ubiquitin ligase machinery. Drugs like IMiDs act as molecular glues that bind the CRBN subunit, creating a new interface that recruits neo-substrates (e.g., IKZF1, IKZF3) for ubiquitination and degradation [4, 5]. PROTACs use the complex to recruit specific proteins of interest for targeted degradation [7].
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cereblon-Cullin 4 E3 ubiquitin ligase complex (CRL4-CRBN) (CRL4-CRBN).